Symbiosis bolsters in-house analytical testing with £1M investment

Image: Symbiosis facility at Stirling Innovation Park in Scotland, UK

The investment will give Symbiosis greater control over sample testing timelines 

This investment will see the introduction of in-house testing capabilities for both analytical chemistry and microbiology, and will include dedicated microbiology laboratories as well as temperature and humidity-controlled stability storage capabilities. These will be located adjacent to the company’s existing GMP manufacturing suites in Stirling, Scotland. 

Construction of the laboratories began in June of this year and the first microbiology testing capabilities will be qualified and available to support an international client base from the first quarter of 2023. Further microbiology and chemistry capabilities will be qualified and introduced throughout 2023.  

Symbiosis also announced the appointment of Alison Clayton as Head of Analytical Services to lead the expansion of analytical testing capabilities. She said the company would take a phased approach to building in-house chemistry and microbiology laboratory capabilities and will eventually offer ‘an enhanced suite of testing capabilities, including sterility, bioburden and endotoxin testing as well as analytical chemistry.’ 

The company is expected to hire up to 20 additional skilled life sciences staff by the end of next year to support this new testing capability.  

CEO of Symbiosis, Colin MacKay commented: ‘This investment is another clear statement of our continuing ambition to strengthen our service offering in response to the demands from existing clients and to position Symbiosis to attract further global biotechnology and pharmaceutical clients in the future.’ 

The new laboratories will be located in the Logie Court building, one of the three buildings on the Stirling Innovation Park in the UK from which Symbiosis operates.